盤中異動 | 阿裏健康盤中下跌8%,報於9.04港元
2021年11月1日13時3分,阿裏健康(HK00241)盤中下跌8%,報於9.04港元,成交額達2.44億港元,換手率達到0.19%。
10月29日訊,中金髮表報告指,近日國家衛健委發佈關於互聯網診療監管細則(徵求意見稿),預計隨着線上覆診行爲流程的監管落地,行業中部分不規範的線上問診行爲或將在短期內解決,並對處方藥銷售的增量業務的放量節奏有一定程度負面影響,而對具備完善合規監管體系,完備診療購藥流程手段的頭部公司,集中度長期或將進一步提升。該行推薦京東健康(06618.HK),阿裏健康(00241.HK),並建議關注平安好醫生(01833.HK)。
10月27日,瑞信:維持阿裏健康(00241)“跑贏大市”評級,目標價削29%至15港元。10月27日,美銀證券:重申阿裏健康(00241)“買入”評級,目標價降17.4%至19港元。10月19日,國信證券:首予阿裏健康(00241)“增持”評級,價值區間11.58-14.6港元。
最新的財務數據顯示,公司於2021年1季度,營業收入155.18億人民幣,淨利潤3.43億人民幣;營業收入同比增加61.71%,毛利潤同比增加61.85%,淨利潤同比增加2283.23%。
盈立趨勢長盈模型最近一次交易信號,2021年10月27日出現觀望信號,觸發價格爲10.32港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.